Difference between revisions of "Team:SCUT-China B/Crispri"

Line 430: Line 430:
 
<body>
 
<body>
 
<div class="nav">
 
<div class="nav">
−
         <li><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li>
+
         <li style="width:10%;"><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li>
 
         <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li>
 
         <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li>
−
         <li><a href="../home.html">Home</a></li>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B">Home</a></li>
−
         <li><a href="overview.html">Project</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Project</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="overview.html">Overview</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Overview</a></li>
−
                 <li><a href="propoptosis.html">Apoptosis Induction</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</a></li>
−
                 <li><a href="protumor.html">Tumor specific promoter</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
−
         <li><a href="">Achievements</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Achievements</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="">Results</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Results</a></li>
−
                 <li><a href="parts.html">Parts</a></li>               <li><a href="">Judging</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Parts">Parts</a></li>
 +
                <li><a href="https://2016.igem.org/Team:SCUT-China_B/Judging">Judging</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
−
         <li><a href="modeling.html">Modeling</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Modeling">Modeling</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="apoptosis.html">Apoptosis</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Apoptosis">Apoptosis</a></li>
−
                 <li><a href="crispri.html">CRISPRi/a</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Crispri">CRISPRi/a</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
−
         <li><a href="">Notebook</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Notebook</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="Protocol.html">Protocol</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Protocol</a></li>
−
                 <li><a href="Safety.html">Safety</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Safety">Safety</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
−
         <li><a href="hp.html">Human Practice</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Human Practice</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="hp.html">Overview</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Overview</a></li>
−
                 <li><a href="hp1.html">Project Design</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP1">Project Design</a></li>
−
                 <li><a href="hp2.html">Hospice Care</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP2">Public Outreach</a></li>
−
                 <li><a href="hp3.html">Public Outreach</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP3">Hospice Care</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>
−
         <li><a href="">Lab</a>
+
         <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Lab</a>
−
             <ul>
+
             <ul class="ultop">
−
                 <li><a href="team.html">Team</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Team</a></li>
−
                 <li><a href="Collaborations.html">Collaborations</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Collaborations">Collaborations</a></li>
−
                 <li><a href="Attributions.html">Attributions</a></li>
+
                 <li><a href="https://2016.igem.org/Team:SCUT-China_B/Attributions">Attributions</a></li>
 
             </ul>
 
             </ul>
 
         </li>
 
         </li>

Revision as of 18:02, 28 November 2016

IGEM-China_B

  • logo
  • logo
  • Home
  • Project
  • Achievements
  • Modeling
  • Notebook
  • Human Practice
  • Lab
    • Overview
    CRISPRi/a
    Model Formation
    Equations and Parameters
    Parameters Optimization
    Tumor Specific CRISPRa
    Model Formation
    Equations and Parameters
    References

    CRISPRi/a

    CRISPRi: bcl-2 repression

    CRISPRi is to use dCas9-KRAB to block the RNA polymerase transcription elongation and initialization. We till several sgRNAs or single sgRNA in the bcl-2 promoter to obtaion optimal repression. We create the CRISPRi model with mass action laws in order to gain fold repression of bcl-2

    CRISPRa: bax activation 

    CRISPRa is to use dCas9-VP64 to activate the transcription initialization. We use the similar stragegy to obtain optimal activation. And we create CRISPRa model with mass action laws in order to gain fold activation of bax.

    The tumor specific promoter in our project is with an ampilification system. It contains a minimal promoter targeted by three dCas9-VP64-sgRNA complex. We build a two-step-transcription-activation model to analyze whether it can promote enough dCas9-VP64.

    We build up a model for tumor specific promoter that expresses the CRISPR/dCas9-VP96 system.

    The dCas9-VP64-GFP expression rate under EF1α promoter, survivin promoter, and Bax_1 promoter.